

# Jordi Barretina Ginesta

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4060995/publications.pdf>

Version: 2024-02-01

57  
papers

25,385  
citations

70961

41  
h-index

123241

61  
g-index

66  
all docs

66  
docs citations

66  
times ranked

40971  
citing authors

#	ARTICLE	IF	CITATIONS
1	The effect of external stimulation on functional networks in the aging healthy human brain. <i>Cerebral Cortex</i> , 2022, 33, 235-245.	1.6	8
2	Whole-Brain Dynamics in Aging: Disruptions in Functional Connectivity and the Role of the Rich Club. <i>Cerebral Cortex</i> , 2021, 31, 2466-2481.	1.6	29
3	E3 ubiquitin ligase Atrogin-1 mediates adaptive resistance to KIT-targeted inhibition in gastrointestinal stromal tumor. <i>Oncogene</i> , 2021, 40, 6614-6626.	2.6	7
4	Whole-genome analysis of Nigerian patients with breast cancer reveals ethnic-driven somatic evolution and distinct genomic subtypes. <i>Nature Communications</i> , 2021, 12, 6946.	5.8	22
5	The Aging Imageomics Study: rationale, design and baseline characteristics of the study population. <i>Mechanisms of Ageing and Development</i> , 2020, 189, 111257.	2.2	18
6	Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer. <i>Oncogene</i> , 2019, 38, 6399-6413.	2.6	160
7	Germline variants and somatic mutation signatures of breast cancer across populations of African and European ancestry in the US and Nigeria. <i>International Journal of Cancer</i> , 2019, 145, 3321-3333.	2.3	16
8	Next-generation characterization of the Cancer Cell Line Encyclopedia. <i>Nature</i> , 2019, 569, 503-508.	13.7	2,149
9	The landscape of cancer cell line metabolism. <i>Nature Medicine</i> , 2019, 25, 850-860.	15.2	350
10	Characterization of Nigerian breast cancer reveals prevalent homologous recombination deficiency and aggressive molecular features. <i>Nature Communications</i> , 2018, 9, 4181.	5.8	77
11	EGF816 Exerts Anticancer Effects in Non-EGFR Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF Receptor. <i>Cancer Research</i> , 2016, 76, 1591-1602.	0.4	103
12	Identification of ALK Gene Alterations in Urothelial Carcinoma. <i>PLoS ONE</i> , 2014, 9, e103325.	1.1	9
13	An Interactive Resource to Identify Cancer Genetic and Lineage Dependencies Targeted by Small Molecules. <i>Cell</i> , 2013, 154, 1151-1161.	13.5	615
14	Global chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic leukemia. <i>Nature Genetics</i> , 2013, 45, 1386-1391.	9.4	238
15	Genomic Medicine Frontier in Human Solid Tumors: Prospects and Challenges. <i>Journal of Clinical Oncology</i> , 2013, 31, 1874-1884.	0.8	101
16	NF1 Deletion Generates Multiple Subtypes of Soft-Tissue Sarcoma That Respond to MEK Inhibition. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 1906-1917.	1.9	73
17	Gastrointestinal Adenocarcinomas of the Esophagus, Stomach, and Colon Exhibit Distinct Patterns of Genome Instability and Oncogenesis. <i>Cancer Research</i> , 2012, 72, 4383-4393.	0.4	242
18	Melanoma genome sequencing reveals frequent PREX2 mutations. <i>Nature</i> , 2012, 485, 502-506.	13.7	671

#	ARTICLE	IF	CITATIONS
19	Wnt-Pathway Activation in Two Molecular Classes of Hepatocellular Carcinoma and Experimental Modulation by Sorafenib. <i>Clinical Cancer Research</i> , 2012, 18, 4997-5007.	3.2	251
20	The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. <i>Nature</i> , 2012, 483, 603-607.	13.7	6,473
21	Nuclear factor I/B is an oncogene in small cell lung cancer. <i>Genes and Development</i> , 2011, 25, 1470-1475.	2.7	142
22	Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. <i>Nature</i> , 2011, 476, 346-350.	13.7	1,359
23	Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion. <i>Nature Genetics</i> , 2011, 43, 964-968.	9.4	270
24	Advances in sarcoma genomics and new therapeutic targets. <i>Nature Reviews Cancer</i> , 2011, 11, 541-557.	12.8	364
25	Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 12372-12377.	3.3	383
26	Strong expression of IGF1R in pediatric gastrointestinal stromal tumors without <i>IGF1R</i> genomic amplification. <i>International Journal of Cancer</i> , 2010, 127, 2718-2722.	2.3	62
27	The landscape of somatic copy-number alteration across human cancers. <i>Nature</i> , 2010, 463, 899-905.	13.7	3,331
28	COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. <i>Nature</i> , 2010, 468, 968-972.	13.7	1,325
29	Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. <i>Nature Genetics</i> , 2010, 42, 715-721.	9.4	642
30	Integrative analysis of the melanoma transcriptome. <i>Genome Research</i> , 2010, 20, 413-427.	2.4	248
31	Amplification of chromosomal segment 4q12 in non-small cell lung cancer. <i>Cancer Biology and Therapy</i> , 2009, 8, 2042-2050.	1.5	78
32	Evidence that Inositol Polyphosphate 4-Phosphatase Type II Is a Tumor Suppressor that Inhibits PI3K Signaling. <i>Cancer Cell</i> , 2009, 16, 115-125.	7.7	411
33	The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer. <i>Nature Genetics</i> , 2009, 41, 882-884.	9.4	616
34	Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. <i>Journal of Clinical Investigation</i> , 2009, 119, 1727-1740.	3.9	230
35	CDK8 is a colorectal cancer oncogene that regulates $\beta$ -catenin activity. <i>Nature</i> , 2008, 455, 547-551.	13.7	594
36	Focal Gains of <i>VEGFA</i> and Molecular Classification of Hepatocellular Carcinoma. <i>Cancer Research</i> , 2008, 68, 6779-6788.	0.4	589

#	ARTICLE	IF	CITATIONS
37	CDYL Bridges REST and Histone Methyltransferases for Gene Repression and Suppression of Cellular Transformation. <i>Molecular Cell</i> , 2008, 32, 718-726.	4.5	133
38	Functional Copy-Number Alterations in Cancer. <i>PLoS ONE</i> , 2008, 3, e3179.	1.1	142
39	Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 20007-20012.	3.3	927
40	High-throughput oncogene mutation profiling in human cancer. <i>Nature Genetics</i> , 2007, 39, 347-351.	9.4	927
41	R5 HIV gp120-mediated cellular contacts induce the death of single CCR5-expressing CD4 T cells by a gp41-dependent mechanism. <i>Journal of Leukocyte Biology</i> , 2004, 76, 804-811.	1.5	51
42	Immunological and virological study of enfuvirtide-treated HIV-positive patients. <i>Aids</i> , 2004, 18, 1673-1682.	1.0	31
43	High Level of Coreceptor-independent HIV Transfer Induced by Contacts between Primary CD4 T Cells. <i>Journal of Biological Chemistry</i> , 2004, 279, 51305-51314.	1.6	89
44	Cell-Surface-Expressed HIV-1 Envelope Induces the Death of CD4 T Cells during GP41-Mediated Hemifusion-like Events. <i>Virology</i> , 2003, 305, 318-329.	1.1	70
45	Interleukin-7-Dependent Production of RANTES That Correlates with Human Immunodeficiency Virus Disease Progression. <i>Journal of Virology</i> , 2003, 77, 4389-4395.	1.5	23
46	Anti-HIV-1 activity of enfuvirtide (T-20) by inhibition of bystander cell death. <i>Antiviral Therapy</i> , 2003, 8, 155-61.	0.6	7
47	Anti-HIV-1 Activity of Enfuvirtide (T-20) by Inhibition of Bystander Cell Death. <i>Antiviral Therapy</i> , 2003, 8, 155-161.	0.6	25
48	Reduced Fitness of HIV-1 Resistant to Cxcr4 Antagonists. <i>Antiviral Therapy</i> , 2003, 8, 1-8.	0.6	51
49	Preferential Attachment of HIV Particles to Activated and CD45RO+CD4+T Cells. <i>AIDS Research and Human Retroviruses</i> , 2002, 18, 27-38.	0.5	12
50	Anti-HIV activity of a novel aminoglycoside-arginine conjugate. <i>Antiviral Research</i> , 2002, 53, 1-8.	1.9	31
51	Sequential involvement of Cdk1, mTOR and p53 in apoptosis induced by the HIV-1 envelope. <i>EMBO Journal</i> , 2002, 21, 4070-4080.	3.5	146
52	Interleukin-7 in Plasma Correlates with CD4 T-Cell Depletion and May Be Associated with Emergence of Syncytium-Inducing Variants in Human Immunodeficiency Virus Type 1-Positive Individuals. <i>Journal of Virology</i> , 2001, 75, 10319-10325.	1.5	127
53	CD4+ and CD8+ T Cell Death during Human Immunodeficiency Virus Infection in Vitro. <i>Virology</i> , 2001, 285, 356-365.	1.1	19
54	Human Immunodeficiency Virus 1 Envelope Glycoprotein Complex-Induced Apoptosis Involves Mammalian Target of Rapamycin/Fkbp12-Rapamycin-Associated Protein-Mediated P53 Phosphorylation. <i>Journal of Experimental Medicine</i> , 2001, 194, 1097-1110.	4.2	147

#	ARTICLE	IF	CITATIONS
55	Stromal-cell-derived factor 1 prevents the emergence of the syncytium-inducing phenotype of HIV-1 in vivo. <i>Aids</i> , 2001, 15, 1890-1892.	1.0	15
56	The CXCR4 Antagonist AMD3100 Efficiently Inhibits Cell-Surface-Expressed Human Immunodeficiency Virus Type 1 Envelope-Induced Apoptosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2000, 44, 51-56.	1.4	59
57	Anti-Human Immunodeficiency Virus Activity of Novel Aminoglycoside-Arginine Conjugates at Early Stages of Infection. <i>AIDS Research and Human Retroviruses</i> , 2000, 16, 627-634.	0.5	36